- Home
- PSTV vs ADAG Comparison
PSTV vs ADAG Comparison
Compare PSTV & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSTV | ADAG |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.4M | 90.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSTV | ADAG |
|---|---|---|
| Price | $0.24 | $2.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $6.75 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 18.2M | 211.8K |
| Earning Date | 10-30-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,258,000.00 | $103,204.00 |
| Revenue This Year | $1.73 | $4,446.34 |
| Revenue Next Year | $12.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $1.30 |
| 52 Week High | $2.31 | $3.16 |
Technical Indicators
Market Signals| Indicator | PSTV | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 25.75 | 72.46 |
| Support Level | $0.22 | $1.69 |
| Resistance Level | $0.25 | $2.94 |
| Average True Range (ATR) | 0.03 | 0.37 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 10.34 | 83.54 |
Price Performance
Historical ComparisonAbout PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.